ライフサイエンスコーパス: polymyxin B

1 xycholate and showed increased resistance to polymyxin B.

2 ated flagellin in the presence or absence of polymyxin B.

3 hoxazole and, like other S. aureus isolates, polymyxin B.

4 and El Tor V. cholerae mutants sensitive to polymyxin B.

5 unced synergy was noted with tigecycline and polymyxin B.

6 to beta-sheet defensin HNP-1 and lipopeptide polymyxin B.

7 e to the CAMPs nisin and gallidermin but not polymyxin B.

8 times more resistant than wild-type cells to polymyxin B.

9 in FA19) resistance to normal human serum or polymyxin B.

10 sion in CLP-induced sepsis was attenuated by polymyxin B.

11 binding affinity for LPS similar to that of polymyxin B.

12 ized by pretreating CLP-induced WT mice with polymyxin B.

13 tions mediating resistance to the antibiotic polymyxin B.

14 ericidal/permeability increasing protein and polymyxin B.

15 was more sensitive to cecropin A, but not to polymyxin B.

16 imilar to that achieved with 10 microg/mL of polymyxin B.

17 tion from the cationic antimicrobial peptide polymyxin B.

18 resistance to antimicrobial peptides such as polymyxin B.

19 inhibitable with TLR4-specific antibody and polymyxin B.

20 rivatives with affinity greater than that of polymyxin B.

21 to the antimicrobial peptides magainin 2 and polymyxin B.

22 ipid A molecules and are more susceptible to polymyxin B.

23 tions mediating resistance to the antibiotic polymyxin B.

24 a-sheet defensins and the cyclic lipopeptide polymyxin B.

25 almonella resistance to the cationic peptide polymyxin B.

26 Salmonella minnesota, was not suppressed by polymyxin B.

27 by the killed bacteria was not inhibited by polymyxin B.

28 ther anti-TLR4 blocking antibody (HTA125) or Polymyxin B.

29 ysaccharide and resistance to the antibiotic polymyxin B.

30 affected by the lipopolysaccharide inhibitor polymyxin B.

31 manner and was inhibited by the addition of polymyxin B.

32 the testing of the polymyxins, colistin and polymyxin B.

33 ed little NO), regardless of the presence of polymyxin B.

34 most completely inhibited in the presence of polymyxin B.

35 affected by the pharmacologic LPS antagonist polymyxin B.

36 in mRNA expression, which was ameliorated by polymyxin B.

37 bocyte lysate assay, and can be inhibited by polymyxin B.

38 nt and was not diminished by the presence of polymyxin B.

39 otoxins with a potency comparable to that of polymyxin B.

40 ction at 6 to 10 h, and was not inhibited by polymyxin B.

41 toxin-induced effects) were not inhibited by polymyxin B.

42 lls is hampered by the well-known antibiotic polymyxin B.

43 ram-negative-targeted antimicrobials such as polymyxin B.

44 cretion with a potency comparable to that of polymyxin B.

45 r and in E. coli treated with P1vir phage or polymyxin B.

46 bute to the organism's natural resistance to polymyxin B.

47 inicians are increasingly using colistin and polymyxin B.

48 VI secretion system (T6SS), P1vir phage, and polymyxin B.

49 hances resistance to the cationic antibiotic polymyxin B.

50 tween SPLUNC1 and LPS, lipoteichoic acid, or polymyxin B.

51 MacA protein with affinity exceeding that of polymyxin B.

52 showed a 100-fold increase in sensitivity to polymyxin B.

53 heir resistance to the antimicrobial peptide polymyxin B.

54 tients aged 21-87 years received intravenous polymyxin B (0.45-3.38 mg/kg/day).

55 , 0.25 to 1 microg/ml (11 to 17 mm), and for polymyxin B, 0.25 to 2 microg/ml (13 to 19 mm).

56 , 0.25 to 2 microg/ml (11 to 17 mm), and for polymyxin B, 0.25 to 2 mug/ml (14 to 18 mm).

57 Interestingly, polymyxin B (5 microg/ml) and RsDPLA show only a limited

58 omol/L) or by the protein kinase C inhibitor polymyxin B (50 micromol/L).

59 creased in the presence of the PKC inhibitor polymyxin B (50+/-6%), suggesting that if activation of

60 ajor errors were noted for colistin (5%) and polymyxin B (6%).

61 ospholipid probe to elucidate the effects of polymyxin-B (a cytolytic peptide), valproic acid (a lipo

62 Polymyxin B, a cationic peptide antibiotic, is one of th

63 e antibiotic interactions between OM-SBs and polymyxin B, a cationic peptide used to treat Gram-negat

64 , the activity was dramatically inhibited by polymyxin B, a relatively specific inhibitor of endotoxi

65 Polymyxin B added in the incubation media abolished the

66 Polymyxin B addition engendered Escherichia coli and Pse

67 imicrobial agents for potential synergy with polymyxin B against 12 clinical strains of carbapenemase

68 ve rods and only 7 grew on mannitol-egg yolk-polymyxin B agar and/or the Anthracis chromogenic agar.

69 S depletion of S. marcescens secretomes with polymyxin B agarose rendered secretomes unable to inhibi

70 Removal of LPS from rhHsp70-2 by polymyxin B-agarose column or direct addition of polymyx

71 sentially eliminated after passing through a polymyxin B-agarose column that removes LPS and LPS-asso

72 es of experiments, both free polymyxin B and polymyxin B-agarose stimulated mitochondrial glycerophos

73 ethylenimine, polyamidoamine dendrimers, and polymyxin B, although they attenuate thrombosis, all hav

74 After the antimicrobial mixture of polymyxin B, amphotericin B, nalidixic acid, trimethopri

75 e BACTEC 12B medium including PANTA reagent (polymyxin B, amphotericin B, nalidixic acid, trimethopri

76 ed NF-kappaB activation was not inhibited by polymyxin B, an antibiotic that binds and neutralizes LP

77 living bacteria was partially suppressed by polymyxin B, an inhibitor of LPS, but did not require se

78 and immature populations was not blocked by polymyxin B, an inhibitor of LPS.

79 Polymyxin B, an LPS blocker, did not affect ESAT-6 stimu

80 n the presence of the LPS-binding antibiotic polymyxin B and a potent LPS antagonist, E5564, which co

81 sitivity to sodium dodecyl sulfate (SDS) and polymyxin B and also had a reduced competitive index com

82 ed to mimic the lipid A binding character of polymyxin B and are shown to bind lipid A derivatives wi

83 ts, and resistance to antimicrobial peptides polymyxin B and avian beta-defensins.

84 by cationic antimicrobial peptides, such as polymyxin B and beta-defensins.

85 susceptibility to the antimicrobial peptides polymyxin B and cathelicidin-related antimicrobial pepti

86 o polymyxin B, and some were less toxic than polymyxin B and colistin against mammalian HepG2 cells a

87 Polymyxin B and colistin displayed a nearly identical sp

88 erent clinically relevant dosage regimens of polymyxin B and colistin over 96 h.

89 ncreasing reliance on polymyxin antibiotics (polymyxin B and colistin) for treatment of multidrug-res

90 cinetobacter baumannii strains, resistant to polymyxin B and colistin, and 20 A. baumannii worldwide

91 d in resistance to the antimicrobial peptide polymyxin B and critical for replication in macrophages

92 of polymyxin B and rifampin as well as with polymyxin B and doxycycline, resulting in at least a 4-f

93 y classical V. cholerae mutants resistant to polymyxin B and El Tor V. cholerae mutants sensitive to

94 ed by colony counts following treatment with polymyxin B and gentamicin.

95 t due to endotoxin, since preincubation with polymyxin B and HrHRF gave similar results to that with

96 is study, we investigated the interaction of polymyxin B and human neutrophil peptide (HNP-1) with th

97 lly diverse cationic antimicrobial peptides (polymyxin B and LL-37) but not to antibiotics that exert

98 ic studies of these lipid A derivatives with polymyxin B and polymyxin B nonapeptide indicate that bi

99 e ionic interactions dominate association of polymyxin B and polymyxin B nonapeptide with lipid A.

100 In another series of experiments, both free polymyxin B and polymyxin B-agarose stimulated mitochond

101 e of S. enterica serovar Typhimurium to both polymyxin B and protegrin-1.

102 to handle the antibacterial cationic peptide polymyxin B and reactive nitrogen and oxygen radicals an

103 in particular exhibited hypersensitivity to polymyxin B and reduced survival in mice.

104 Synergy was observed with the combination of polymyxin B and rifampin as well as with polymyxin B and

105 irulence factor expression and resistance to polymyxin B and serum and in vivo colonization levels si

106 e was developed in which graded dilutions of polymyxin B and the study drug were incubated with resis

107 Polymyxin B and tigecycline were the second most active

108 embrane protein, OmpU, confers resistance to polymyxin B and to a bioactive peptide (P2) derived from

109 ontrols resistance to the peptide antibiotic polymyxin B and to several antimicrobial proteins from h

110 ontrols resistance to the peptide antibiotic polymyxin B and to several antimicrobial proteins from h

111 stelae, and H. muridarum became sensitive to polymyxin B and/or trimethoprim.

112 ) and neutrophils (hNP-1) and from bacteria (polymyxin B), and (iv) the synthesis and translocation o

113 il infiltration, were treated by vancomycin, polymyxin B, and Abx (ampicillin, neomycin, metronidazol

114 uitment, enhancing antibacterial activity of polymyxin B, and blocking the function of the Shigella o

115 ell wall antibiotics including beta-lactams, polymyxin B, and d-cycloserine.

116 antibiotics (intravenous penicillin, topical polymyxin B, and gentamicin sulfate) were administered.

117 ferences between parenteral CMS/colistin and polymyxin B, and highlight the clinical implications.

118 sensitive to the cationic peptides melittin, polymyxin B, and poly-l-lysine, in a manner that paralle

119 or better antimicrobial potency compared to polymyxin B, and some were less toxic than polymyxin B a

120 Prenatal neomycin, polymyxin B, and streptomycin treatment protected NOD mi

121 combination of three antibiotics--neomycin, polymyxin B, and streptomycin--on diabetes development.

122 in, eravacycline, minocycline, omadacycline, polymyxin B, and tigecycline.

123 to high salt and calcium concentrations, to polymyxin B, and to caffeine.

124 ly increased susceptibilities to daptomycin, polymyxin B, and two prototypical HD-CAPs (hNP-1 and RP-

125 , and three peptide antibiotics (bacitracin, polymyxin B, and vancomycin).

126 ive to the cationic peptides, poly-l-lysine, polymyxin-B, and melittin.

127 hocolate agar, BCYE, and selective BCYE with polymyxin B, anisomycin, and vancomycin) and on axenic a

128 ere parenteral products of both colistin and polymyxin B are available, prospective studies should be

129 Our study showed that doses of intravenous polymyxin B are best scaled by total body weight.

130 ulted in a strain that was as susceptible to polymyxin B as a phoP mutant.

131 pbgP and ugd mutants are not as sensitive to polymyxin B as a pmrA mutant.

132 tion process was optimized by using EDTA and polymyxin B as a sensitizer to improve the accuracy of d

133 Polymyxin B as an antiendotoxin strategy has an unaccept

134 is required for resistance to the antibiotic polymyxin B, as mutations of the PmrA-activated pbg oper

135 ed in increased gonococcal susceptibility to polymyxin B, as reported previously for Neisseria mening

136 ivity to the cationic antimicrobial peptide, polymyxin B, as well as a decrease in motility.

137 been previously implicated in resistance to polymyxin B, as well as dephosphorylation of the Hep(II)

138 Polymyxin B binds to and disrupts ExPortal integrity, re

139 Consistently, polymyxin B blocked the enzymatic activity of Stx1, Stx2

140 Antibody and polymyxin B blocking of the Toll-like receptor 4 (TLR4)

141 Also, all mutants exhibited sensitivity to polymyxin B but did not display sensitivity to deoxychol

142 ability to activate DC was not eliminated by polymyxin B but was destroyed by proteinase K.

143 exposure to the CAPs, RP-1 (platelets), and polymyxin B, but not by other cationic molecules (hNP-1,

144 red Salmonella susceptible to magainin 2 and polymyxin B, but not defensin HNP-1.

145 nent regulatory system governs resistance to polymyxin B by controlling transcription of the 4-aminoa

146 ith the P. aeruginosa outer membrane such as polymyxin B can also trigger assembly of T6SS organelles

147 experiments on nonmotile E. coli exposed to polymyxin B, cell-generated frequency noise dropped clos

148 ect to sensitivity to the peptide antibiotic polymyxin B: classical strains are sensitive and El Tor

149 A 2-hydroxylation protects A. baumannii from polymyxin B, colistin, and human beta-defensin 3.

150 ffinity chromatography, and passed through a polymyxin B column to remove contaminating lipopolysacch

151 e and significantly increased sensitivity to polymyxin B compared to the parental strain.

152 splayed >1,000-fold increased sensitivity to polymyxin B compared to the parental Y. pestis strain, K

153 ent with H2A and the pore-forming antibiotic polymyxin B completely eradicates bacterial growth.

154 Polymyxin B completely inhibited LOS stimulation but onl

155 Polymyxin B concentrations were measured by liquid chrom

156 cules were further tagged with antimicrobial polymyxin-B conjugated gold nanoparticles (PMB-AuNPs) in

157 dromal intestinal phase, and the toxicity of polymyxin B could further discourage its therapeutic use

158 Only polymyxin B could reduce hepatic lymphocytes in WD-fed F

159 ased resistance to the CAMPs gallidermin and polymyxin B, demonstrating tolerance to different types

160 confound the results, as preincubation with polymyxin B did not change iNOS or TNF protein levels.

161 ect LPS interaction since it, in contrast to polymyxin B, displayed only minor activity in the Limulu

162 Polymyxin B dosage regimens that achieved peak concentra

163 in the study; 29 patients used trimethoprim/polymyxin B drops, and 11 patients used fluoroquinolone

164 ype (WT) was significantly more sensitive to polymyxin B, ethanol, and high-temperature stresses.

165 phorelay, which contributes to survival from polymyxin B exposure.

166 ) endotoxin was monitored using a dansylated polymyxin B fluorochrome agent.

167 reduced the ability of Salmonella to survive polymyxin B following addition of adrenaline.

168 on of the relative merits of colistin versus polymyxin B for various types of infection; investigatio

169 for povidone-iodine and 7 days for neomycin-polymyxin B-gramicidin (95% confidence interval [CI] for

170 ith povidone-iodine or antibiotics (neomycin-polymyxin B-gramicidin in the Philippines; ciprofloxacin

171 atment of STF abrogated their effects, while polymyxin B had no effect.

172 cation of lipid A plays in the resistance to polymyxin B has remained unknown.

173 We put forth the view that overall polymyxin B has superior clinical pharmacological proper

174 The polymyxin lipodecapeptides colistin and polymyxin B have become last resort therapies for infect

175 Colistin and polymyxin B have indistinguishable microbiological activ

176 ality was 0.81 (95% CI, 0.70-0.95), favoring polymyxin B hemoperfusion (p = 0.007).

177 ults were mainly influenced by studies using polymyxin B hemoperfusion from Japan.

178 Studies investigating the effect of polymyxin B hemoperfusion on mortality were considered e

179 studies have reported a survival benefit for polymyxin B hemoperfusion treatment in patients with sev

180 The present study demonstrated that polymyxin B hemoperfusion treatment may reduce mortality

181 ate meta-analysis to determine the effect of polymyxin B hemoperfusion treatment on mortality in pati

182 olled trial reported no survival benefit for polymyxin B hemoperfusion treatment.

183 sepsis and septic shock and terms related to polymyxin B hemoperfusion.

184 trials, n=457) after excluding trials using polymyxin B hemoperfusion.

185 rapy comprising direct hemoperfusion using a polymyxin B-immobilized fiber column (PMX-DHP) and susta

186 ne and protegrin, mig-14 is still induced by polymyxin B in a phoP background.

187 , and tigecycline may be useful additions to polymyxin B in the treatment of infections caused by hig

188 erstanding of the antibacterial mechanism of polymyxin B, including disruption kinetics and changes i

189 to adhere to denatured collagen in serum and polymyxin B independent fashion, a property distinct fro

190 e significantly reduced by oral neomycin and polymyxin B, indicating a pathogenetic role of gut-deriv

191 lipid A profile and in its susceptibility to polymyxin B, indicating that the PmrA-dependent modifica

192 the kinetics of induction and sensitivity to polymyxin B inhibition.

193 Second, a heat-labile but polymyxin B-insensitive factor present in supernatants f

194 To better understand lipid A-polymyxin B interaction, pure lipid A derivatives were p

195 Polymyxin B is a last-line therapy for multidrug-resista

196 Polymyxin B is administered directly as the active antib

197 Cell sensitivity to the antimicrobial polymyxin B is affected by LPS modifications, and cells

198 as bile salts and the antimicrobial peptide polymyxin B is increased, and periplasmic constituents l

199 Polymyxin B is one of the few antimicrobials that retain

200 lity testing of the polymyxins (colistin and polymyxin B) is challenging for clinical laboratories.

201 omonas aeruginosa porins, in the presence of polymyxin B, it was possible to induce concentration-dep

202 l patients receiving intravenous colistin or polymyxin B; it occurred in 60.4% and 41.8%, respectivel

203 Pretreatment with polymyxin B (lipopolysaccharide [LPS] inhibitor) did not

204 iteria for colistin (</=11 and >/=14 mm) and polymyxin B (</=10 and >/=14 mm) were suggested, but som

205 t the expression of carRS and almEFG and the polymyxin B MIC increased in mutants lacking toxRS or le

206 KPC) genes by real-time PCR and had elevated polymyxin B MIC values ranging from 16 to 128 mug/ml.

207 sulting in at least a 4-fold decrease in the polymyxin B MIC.

208 onversely, leuO overexpression decreased the polymyxin B MIC.

209 nes, and carbapenems and susceptible only to polymyxin B (MIC <or= 2 microg/ml) were identified as pa

210 However, polymyxin B MICs are elevated against K. pneumoniae isol

211 ut in no significant change in resistance to polymyxin B. msbB mutants of both biotypes showed decrea

212 procedure, in which cells are incubated with polymyxin B nonapeptide (PMBN), an antibiotic derivative

213 this hypothesis, we measured the ability of polymyxin B nonapeptide (PMBN), to synergize with antibi

214 ese lipid A derivatives with polymyxin B and polymyxin B nonapeptide indicate that binding stoichiome

215 ions dominate association of polymyxin B and polymyxin B nonapeptide with lipid A.

216 biocytin labeling in cells permeabilized by polymyxin B nonapeptide, and the helix packing at the pe

217 than the gold standard permeabilizing agent, polymyxin B nonapeptide.

218 II was released by the antimicrobial peptide polymyxin B or a mouse macrophage antimicrobial peptide

219 ired for resistance to magainin 2 but not to polymyxin B or defensin HNP-1.

220 tibiotics, neutralization of serum LPS using polymyxin B, or removal of LPS signaling components usin

221 regulate resistance to several AP, including polymyxin B (PM).

222 Polymyxin B (PmB) is a "last-line" antibiotic scarcely u

223 Biosensing platforms are functionalized with polymyxin B (PMB), a cyclic peptide antibiotic with high

224 Polymyxin B (PMB), a cyclic, cationic peptide antibiotic

225 and renal cytotoxicity profiles relative to polymyxin B (PMB).

226 und to be highly resistant to the model AMP, polymyxin B (PmB, MICs 64-256 ug ml(-1) ).

227 e and to the antimicrobial cationic peptide, polymyxin B (PmxB).

228 rticles containing last resort antimicrobial polymyxin B (Pol-B).

229 ced by OMV pretreatment with proteinase K or polymyxin B prior to coincubation with IECs.

230 In addition, mig-14 is strongly induced by polymyxin B, protamine, and the mammalian antimicrobial

231 insically highly resistant to CAMPs, such as polymyxin B (PxB) (MIC > or = 512 microg/ml).

232 molecular contacts formed by the antibiotic polymyxin B (PxB) is characterized by kinetic and spectr

233 modification as Ara4N, which greatly affects polymyxin B resistance and murine virulence, neither pmr

234 Both serum and polymyxin B resistance as well as phosphoethanolamine de

235 In this study, we report that CarR confers polymyxin B resistance by positively regulating expressi

236 binding-fold (OB-fold) protein important for polymyxin B resistance in broth and also for virulence i

237 nduces PmrA-activated gene transcription and polymyxin B resistance in response to Fe(3+), but that i

238 important for systemic infection in mice and polymyxin B resistance in vitro.

239 the PmrA/PmrB two-component system governing polymyxin B resistance is induced in low Mg(2+) in a pro

240 binding partner of RcsB, is not required for polymyxin B resistance or survival in mice.

241 anscribed PmrA-activated genes and displayed polymyxin B resistance under the same conditions as Salm

242 analysis indicates that ompD contributes to polymyxin B resistance, and both ydeI and ompD are impor

243 mrA-regulated genes appear to participate in polymyxin B resistance, as pbgP and ugd mutants are not

244 F, another general porin, also contribute to polymyxin B resistance.

245 . pestis responsible for autoaggregation and polymyxin B resistance.

246 acid promotes cellular changes resulting in polymyxin B resistance.

247 the 18 loci encode genes that contribute to polymyxin B resistance.

248 ar Typhimurium lipopolysaccharide leading to polymyxin B resistance.

249 his did not result in a measurable effect on polymyxin B resistance.

250 hanolamine is responsible for PmrA-regulated polymyxin B resistance.

251 of phosphoethanolamine into lipid A and for polymyxin B resistance.

252 at are commonly used to treat cholera and to polymyxin B, resistance to which is used as a marker of

253 hia coli mutant was isolated and shown to be polymyxin B resistant.

254 reen was conducted to select for spontaneous polymyxin B-resistant mutants displaying enhanced ExPort

255 APK inhibitor, U0126, or the LPS antagonist, polymyxin B, resulted in an attenuation of KLF5, p50 and

256 sensitivity to certain stressors, including polymyxin B, SDS, and hydrogen peroxide.

257 Polymyxin B sensitivity assays revealed compromised oute

258 Our results indicate that increased polymyxin B sensitivity of the DeltapgmA mutant is due t

259 olet staining, acryflavin agglutination, and polymyxin B sensitivity studies indicated that RB51WboA

260 king almE, almF, and almG exhibited enhanced polymyxin B sensitivity.

261 rae cell envelope by chemical treatment with polymyxin B similarly results in induction of the RpoE-m

262 nsitive to bile salt stress but resistant to polymyxin B stress, indicating OmpU is not essential for

263 odecyl sulfate and the antimicrobial peptide polymyxin B, suggesting a compromise to membrane stabili

264 hage inflammatory protein 2 not inhibited by polymyxin B, suggesting that leptospiral lipopolysacchar

265 mutant was hypersensitive to magainin 2 and polymyxin B, suggesting that the virulence attenuation e

266 ) preconjugated to an antibiotic drug called polymyxin B sulfate (PMB).

267 The secretagogue was polymyxin B sulfate (Pmx).

268 OmpU also conferred resistance to polymyxin B sulfate, suggesting that this porin may impa

269 LPS-chelating antibiotic, polymyxin B, suppressed the antiapoptotic activity, indi

270 g; Etest provided a conservative estimate of polymyxin B susceptibility.

271 pH 5.8 were > 100 000-fold more resistant to polymyxin B than organisms grown at pH 7.7.

272 producing Klebsiella pneumoniae isolates for polymyxin B, tigecycline, cefepime, and meropenem.

273 ed by colony counts following treatment with polymyxin B to kill extracellular bacteria.

274 Furthermore, the ability of polymyxin B to neutralize LPS toxicity was identical for

275 Molar comparison of polymyxin B to proanthocyanidins indicated that the Seph

276 myxin B-agarose column or direct addition of polymyxin B to the incubation medium essentially elimina

277 Polymyxin B total body clearance did not show any relati

278 Polymyxin B treatment and boiling of the virus preparati

279 d proteinase K treatment, yet insensitive to polymyxin B treatment, indicating that the induction is

280 /ml/10(6) cells in 24 h), and insensitive to polymyxin B treatment.

281 the infection was treated with amikacin and polymyxin B-trimethoprim, and the ulcer resolved over 3

282 In the case of polymyxin B, true potency may vary by as much as 40% fro

283 tion when testing colistin (polymyxin E) and polymyxin B, two polycationic peptide antimicrobial agen

284 t the therapeutic application of colistin or polymyxin B until disk diffusion test modifications are

285 The resistance rate to colistin/polymyxin B was 16.1%.

286 endotoxin-neutralizing capacity of LF-33 and polymyxin B was attenuated by human serum.

287 that lacked lptA, and greater sensitivity to polymyxin B was consistent with the absence of phosphoet

288 f the antimicrobial activity of colistin and polymyxin B was initiated using 200 bloodstream infectio

289 Polymyxin B was predominantly nonrenally cleared with me

290 Polymyxin B was studied in combination with cefazolin, c

291 duced by membrane-disrupting natural product polymyxin B, we conclude that RP4 induces "donor-directe

292 rogenes, susceptibility testing methods with polymyxin B were analyzed.

293 tx-induced neutrophil responses inhibited by polymyxin B were performed.

294 se demographics, the total body clearance of polymyxin B when scaled by total body weight (population

295 PACs has been shown to compete with that of polymyxin B which is known to bind the lipid A component

296 o hydrolase mutants were highly sensitive to polymyxin B, which could be attributed to a defect in do

297 Third, polymyxin B, which inactivates LPS, blocks the activity

298 Sensitivity to polymyxin B, which was employed as a model cationic, amp

299 However, association of polymyxin B with lipid A is not fully understood, primar

300 e (on a molar basis) to that of colistin and polymyxin B, with an even broader spectrum of activity t